DNA test could predict aspirin benefit in cancer

A simple DNA test could predict whether aspirin will improve a person's chance of surviving bowel cancer, a US study suggests.

DNA testing could be used to identify patients with the PIK3CA mutation (Photograph: Gustoimages/SPL)
DNA testing could be used to identify patients with the PIK3CA mutation (Photograph: Gustoimages/SPL)

People who carry a particular mutated gene linked to 15% to 20% of colorectal cancers saw greater benefit when taking aspirin than those without the mutation, researchers found. The mutation in the PIK3CA gene could be used as a biomarker to spot patients who are more likely to respond to aspirin, they say.

Aspirin is a candidate for adjuvant therapy beside the usual bowel cancer treatments. But colorectal cancer comprises several different diseases, and patients with particular genetic traits respond differently to aspirin.

Survival rates with aspirin are linked to the expression of one such biomarker, the enzyme PTGS2, by tumours. But the results of immunological tests for this marker varied between laboratories, researchers said. This means other biomarkers are needed to identify more consistently those patients who will respond best to aspirin.

In the study, an international team of researchers tested for the presence of the PIK3CA mutation in the DNA of 964 patients with rectal or colon cancer, and compared this with data on aspirin use after diagnosis and survival rates.

They found that patients with the PIK3CA mutation who took aspirin regularly had an 82% lower risk of dying from their cancer than those who did not take aspirin. But patients without this mutation saw no benefit from taking aspirin.

Study authors said the finding should be interpreted with caution, as there were small numbers of deaths in the study, and said it needed to be confirmed by further work.

They concluded: 'PIK3CA mutation may serve as a tumour biomarker that predicts the response to the initiation of aspirin therapy in patients with newly diagnosed colorectal cancer.'

  • NEJM 2012; 367: 1596-1606

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

The healthcare crisis in Myanmar - how UK GPs can help

The healthcare crisis in Myanmar - how UK GPs can help

Dr Jim Brockbank from Myanmar UK GP Health Action provides an update on how the military...

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

GPs warn of 'open floodgates' as 84% say e-consultations have driven up workload

More than four fifths of GPs say e-consultation systems adopted in the pandemic have...

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Map: Which CCGs have the highest COVID-19 vaccine coverage?

Tens of millions of COVID-19 jabs have been administered across England, but how...

Podcast: Greener practice, sharing patient data and additional roles

Podcast: Greener practice, sharing patient data and additional roles

In this episode we look at data extraction from GP records, ask whether the additional...

Red flag symptoms: Loss of consciousness

Red flag symptoms: Loss of consciousness

Red flag symptoms to look out for in presentations of loss of consciousness, including...

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

£20m fund to speed up second jabs as CCGs told to limit pressure on practices

NHS England has announced £20m in funding to help local COVID-19 vaccination sites...